CD137 ligand is expressed in primary and secondary lymphoid follicles and in b-cell lymphomas: Diagnostic and therapeutic implications

American Journal of Surgical Pathology

Volumn 37, Issue 2, 2013, Pages 250-258

  Zhao, Shuchun ^a,b   Zhang, Haiyu ^a   Xing, Ying ^b   Natkunam, Yasodha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

4 1BB ligand; CD137; immunohistochemistry; immunomodulation; lymphoma

Indexed keywords

CD137 LIGAND; TNFSF9 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; B CELL LYMPHOMA; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GERMINAL CENTER; HUMAN; IMMUNOMODULATION; LARGE CELL LYMPHOMA; LYMPHOID TISSUE; MANTLE CELL LYMPHOMA; METABOLISM; PATHOLOGY;

4-1BB LIGAND; FLOW CYTOMETRY; GERMINAL CENTER; HUMANS; IMMUNOMODULATION; LYMPHOID TISSUE; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; TUMOR MARKERS, BIOLOGICAL;

EID: 84872862122     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318268c6ea     Document Type: Article

References (24)

1. Wang C, Lin GH, McPherson AJ, et al. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev. 2009;229:192-215.
2. Wen T, Bukczynski J, Watts TH. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol. 2002;168:4897-4906.
3. Zhang X, Voskens CJ, Sallin M, et al. CD137 promotes proliferation and survival of human B cells. J Immunol. 2010;184:787-795.
4. Lee HW, Park SJ, Choi BK, et al. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol. 2002;169:4882-4888.
5. Lee SW, Croft M. 4-1BB as a Therapeutic Target for Human Disease. Therapeutic Targets of the TNF Superfamily. Boston: Landes Bioscience and Springer Science; 2009:120-129.
6. Thum E, Shao Z, Schwarz H. CD137, implications in immunity and potential for therapy. Front Biosci. 2009;14:4173-4188.
7. DeBenedette MA, Wen T, Bachmann MF, et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol. 1999;163:4833-4841.
8. Mogi S, Sakurai J, Kohsaka T, et al. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology. 2000;101:541-547.
9. Melero I, Bach N, Hellström KE, et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol. 1998;28:1116-1121.
10. Guinn B, DeBenedette MA, Watts TH, et al. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol. 1999;162: 5003-5010.
11. Middendorp S, Xiao Y, Song JY, et al. Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B cell lymphoma. Blood. 2009;114:2280-2289.
12. Alderson MR, Smith CA, Tough TW, et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol. 1994;24:2219-2227.
13. Zhou Z, Kim S, Hurtado J, et al. Characterization of human homologue of 4-1BB and its ligand. Immunol Lett. 1995;45:67-73.
14. Salih HR, Schmetzer HM, Burke C, et al. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol. 2001; 167:4059-4066.
15. Salih HR, Kosowski SG, Haluska VF, et al. Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol. 2000;165:2903-2910.
16. Ek S, Bjorck E, Hogerkorp CM, et al. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer. 2006;118:2092-2097.
17. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
18. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B cell derivation. Blood. 2005;105:3979-3986.
19. Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117:2423-2432.
20. Anderson MW, Zhao S, Freud AG, et al. CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T cell lymphomas. Am J Pathol. 2012. (In press).
21. Alizadeh AA, Gentles AJ, Alencar AJ, et al. Prediction of survival in diffuse large B cell lymphoma based on the expression of two genes reflecting tumor and microenvironment. Blood. 2011;118:1350-1358.
22. Pauly S, Broll K, Wittmann M, et al. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol. 2002;72:35-42.
23. Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B cell lymphomas. Blood. 2007;109:1636-1642.
24. Gratzinger D, Zhao S, West R, et al. The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol. 2009;131:264-278.